Effects of telmisartan on inflammatory cytokines and coronary plaque component as assessed on integrated backscatter intravascular ultrasound in hypertensive patients

Circulation Journal

Volumn 78, Issue 1, 2014, Pages 240-247

  Yamaguchi, Koji ^a   Wakatsuki, Tetsuzo ^a   Soeki, Takeshi ^a   Niki, Toshiyuki ^a   Taketani, Yoshio ^a   Oeduka, Hiroyasu ^a   Kusunose, Kenya ^a   Ise, Takayuki ^a   Iwase, Takashi ^a   Yamada, Hirotsugu ^a   Sata, Masataka ^a  

^a TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Coronary plaque; Inflammatory cytokine; Integrated backscatter intravascular ultrasound; Telmisartan

Indexed keywords

AMLODIPINE; C REACTIVE PROTEIN; CYTOKINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; TELMISARTAN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; CALCIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY PLAQUE; ELASTICITY; FIBROSIS; FOLLOW UP; HUMAN; HYPERTENSION; INTEGRATED BACKSCATTER INTRAVASCULAR ULTRASOUND; INTRAVASCULAR ULTRASOUND; RANDOMIZED CONTROLLED TRIAL; STENT; TREATMENT OUTCOME; VASCULAR DISEASE;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; CORONARY ARTERY DISEASE; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; MALE; PLAQUE, ATHEROSCLEROTIC; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84891099318     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0741     Document Type: Article

References (29)

1. Komiyama N, Berry G, Kolz M, Oshima A, Metz JA, Preuss P, et al. Tissue characterization of atherosclerotic plaques by intravascular ultrasound radio frequency signal analyses: An in vitro study of human coronary arteries. Am Heart J 2000; 140: 565-574.
2. Hiro T, Fujii T, Yasumoto K, Murata T, Murashige A, Matsuzaki M. Detection of fibrous cap in atherosclerotic plaque by intravascular ultrasound by use of color mapping of angle-dependent echo-intensity variation. Circulation 2001; 103: 1206-1211.
3. Schaar AJ, de Korte CL, Mastik F, Strijder C, Pasterkamp G, Boersma E, et al. Characterizing vulnerable plaque features with intravascular elastography. Circulation 2003; 108: 2636-2641.
4. Kawasaki M, Takatsu H, Noda T, Sano K, Ito Y, Hayakawa K, et al. In vivo quantitative tissue characterization of human coronary arterial plaques by use of integrated backscatter intravascular ultrasound and comparison with angioscopic findings. Circulation 2002; 105: 2487-2492.
5. Ohota M, Kawasaki M, Ismail TF, Hattori K, Serruys PW, Ozaki Y. A histological and clinical comparison of new and conventional integrated backscatter intravascular ultrasound (IB-IVUS). Circ J 2012; 76: 1678-1686.
6. Otagiri K, Tsutsui H, Kumazaki S, Miyashita Y, Aizawa K, Koshikawa M, et al. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: Analysis using integrated backscatter IVUS (ELAN study). Circ J 2011; 75: 633-641.
7. Ando H, Amano T, Matsubara T, Uetani T, Nanki M, Marui N, et al. Comparison of tissue characteristics between acute coronary syndrome and stable angina pectoris. An integrated backscatter intravascular ultrasound analysis of culprit and non-culprit lesions. Circ J 2011; 75: 383-390.
8. Nakayama N, Hibi K, Endo M, Miyazawa A, Suzuki H, Maejima N, et al. Validity and reliability of new intravascular ultrasound analysis software for morphological measurement of coronary artery disease. Circ J 2013; 77: 424-431.
9. Muraoka Y, Sonoda S, Kashiyama K, Kamezaki F, Tsuda Y, Araki M, et al. Coronary arterial remodeling and out-stent plaque change after drug-eluting stent implantation: Comparison between zotarolimus-eluting stents and paclitaxel-eluting stents. Circ J 2013; 77: 363-371.
10. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
11. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-677.
12. Yano H, Hibi K, Nozawa N, Ozaki H, Kusama I, Ebina T, et al. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor. Circ J 2012; 76: 1442-1451.
13. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al, REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004; 29: 1071-1080.
14. Kawasaki M, Sano K, Okubo M, Yokoyama H, Ito Y, Murata I, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2005; 45: 1946-1953.
15. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995-1003.
16. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet induced hypercholesterolemia. Circulation 2000; 101: 1586-1593.
17. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 2002; 90: 251-262.
18. Chen J, Li D, Schaefer RF, Mehta JL. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPS expression in Apo-E knockout mice: Novel insights into the role of RAS and dyslipidemia in atherogenesis. J Cardiovasc Pharmacol 2004; 44: 446-452.
19. Luchtefeld M, Grote K, Grothusen C, Bley S, Bandlow N, Selle T, et al. Angiotensin II induces MMP-2 in a p47phox-dependent manner. Biochem Biophys Res Commun 2005; 328: 183-188.
20. Cipollone F, Fazia M, Iezzi A, Pini B, Cuccurullo C, Zucchelli M, et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004; 109: 1482-1488.
21. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
22. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
23. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, et al. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 2006; 72: 184-190.
24. Yamagishi S, Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-2299.
25. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006; 49: 3094-3099.
26. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008; 198: 22-28.
27. Kadowaki T, Yamauchi T. Adiponectin receptors. Endocr Rev 2005; 26: 439-451.
28. Hong SJ, Shim WJ, Choi JI, Joo HJ, Shin SY, Park SM, et al. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol 2007; 100: 1625-1629.
29. Hong SJ, Choi JI, Ahn CM, Park JH, Kim JS, Lim DS. Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients. Heart 2011; 97: 1425-1432.